NYSE:BIO

Bio-Rad Laboratories Stock Forecast, Price & News

$629.59
+3.47 (+0.55 %)
(As of 04/19/2021 05:02 PM ET)
Add
Compare
Today's Range
$621.33
Now: $629.59
$633.63
50-Day Range
$554.11
MA: $577.76
$624.79
52-Week Range
$407.14
Now: $629.59
$689.00
Volume99,494 shs
Average Volume207,977 shs
Market Capitalization$18.79 billion
P/E Ratio5.39
Dividend YieldN/A
Beta0.83
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Bio-Rad Laboratories logo

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP09057220
Phone510-724-7000
Employees8,000
Year Founded1952

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.31 billion
Cash Flow$7.46 per share
Book Value$192.32 per share

Profitability

Net Income$1.76 billion

Miscellaneous

Market Cap$18.79 billion
Next Earnings Date4/29/2021 (Confirmed)
OptionableOptionable

Headlines

Bio-Rad Laboratories, Inc. (NYSE:BIO) Short Interest Update
April 1, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.52 out of 5 stars

Medical Sector

492nd out of 2,024 stocks

Analytical Instruments Industry

11th out of 29 stocks

Analyst Opinion: 2.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -
$629.59
+3.47 (+0.55 %)
(As of 04/19/2021 05:02 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

Is Bio-Rad Laboratories a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bio-Rad Laboratories stock.
View analyst ratings for Bio-Rad Laboratories
or view top-rated stocks.

What stocks does MarketBeat like better than Bio-Rad Laboratories?

Wall Street analysts have given Bio-Rad Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bio-Rad Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 555,000 shares, a decline of 19.0% from the February 28th total of 685,300 shares. Based on an average daily volume of 226,900 shares, the days-to-cover ratio is currently 2.4 days. Approximately 2.6% of the company's stock are short sold.
View Bio-Rad Laboratories' Short Interest
.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Bio-Rad Laboratories
.

How can I listen to Bio-Rad Laboratories' earnings call?

Bio-Rad Laboratories will be holding an earnings conference call on Thursday, April 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) announced its quarterly earnings results on Wednesday, February, 10th. The medical research company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.30 by $0.71. The medical research company earned $789.84 million during the quarter, compared to analysts' expectations of $681.80 million. Bio-Rad Laboratories had a trailing twelve-month return on equity of 3.77% and a net margin of 147.91%.
View Bio-Rad Laboratories' earnings history
.

How has Bio-Rad Laboratories' stock price been impacted by COVID-19?

Bio-Rad Laboratories' stock was trading at $345.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BIO shares have increased by 82.1% and is now trading at $629.59.
View which stocks have been most impacted by COVID-19
.

What guidance has Bio-Rad Laboratories issued on next quarter's earnings?

Bio-Rad Laboratories updated its FY 2021 After-Hours earnings guidance on Thursday, February, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.627-2.639 billion, compared to the consensus revenue estimate of $2.53 billion.

What price target have analysts set for BIO?

3 brokers have issued 12 month target prices for Bio-Rad Laboratories' stock. Their forecasts range from $650.00 to $750.00. On average, they anticipate Bio-Rad Laboratories' share price to reach $700.00 in the next year. This suggests a possible upside of 11.2% from the stock's current price.
View analysts' price targets for Bio-Rad Laboratories
or view top-rated stocks among Wall Street analysts.

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the following people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 71, Pay $3.01M)
  • Mr. Ilan Daskal, Exec. VP & CFO (Age 55, Pay $1.16M) (LinkedIn Profile)
  • Dr. Andrew J. Last, Exec. VP & COO (Age 61, Pay $1.5M) (LinkedIn Profile)
  • Ms. Annette Tumolo, Exec. VP & Pres of Life Science Group (Age 66, Pay $1.05M) (LinkedIn Profile)
  • Ms. Dara Grantham Wright, Exec. VP & Pres of Clinical Diagnostics Group (Age 45, Pay $1.39M) (LinkedIn Profile)
  • Mr. Ajit Ramalingam, Sr. VP & Chief Accounting Officer (Age 48)
  • Diane Dahowski, Sr. VP of Global Technology & Systems
  • Mr. Timothy S. Ernst, Exec. VP, Gen. Counsel & Sec. (Age 61) (LinkedIn Profile)
  • Colleen Corey, Sr. VP of Global HR
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 59) (LinkedIn Profile)

What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?

325 employees have rated Bio-Rad Laboratories CEO Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among Bio-Rad Laboratories' employees.

Who are some of Bio-Rad Laboratories' key competitors?

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional investors include Hexavest Inc. (0.04%), Retirement Systems of Alabama (0.03%), Royal London Asset Management Ltd. (0.02%), State of Alaska Department of Revenue (0.02%), Crossmark Global Holdings Inc. (0.02%) and Strategic Investment Advisors MI (0.00%). Company insiders that own Bio-Rad Laboratories stock include Annette Tumolo, Giovanni Magni, James R Stark, John Hertia, Michael Crowley, Ronald W Hutton and Timothy S Ernst.
View institutional ownership trends for Bio-Rad Laboratories
.

Which institutional investors are selling Bio-Rad Laboratories stock?

BIO stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Crossmark Global Holdings Inc., Retirement Systems of Alabama, Private Capital Group LLC, Pacer Advisors Inc., BTR Capital Management Inc., and Walkner Condon Financial Advisors LLC. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Annette Tumolo, Giovanni Magni, Michael Crowley, and Ronald W Hutton.
View insider buying and selling activity for Bio-Rad Laboratories
or view top insider-selling stocks.

Which institutional investors are buying Bio-Rad Laboratories stock?

BIO stock was bought by a variety of institutional investors in the last quarter, including Everence Capital Management Inc., Redpoint Investment Management Pty Ltd, Royal London Asset Management Ltd., Strategic Investment Advisors MI, State of Alaska Department of Revenue, HighPoint Advisor Group LLC, Atticus Wealth Management LLC, and Fulton Bank N.A..
View insider buying and selling activity for Bio-Rad Laboratories
or or view top insider-buying stocks.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $629.59.

How much money does Bio-Rad Laboratories make?

Bio-Rad Laboratories has a market capitalization of $18.79 billion and generates $2.31 billion in revenue each year. The medical research company earns $1.76 billion in net income (profit) each year or $7.06 on an earnings per share basis.

How many employees does Bio-Rad Laboratories have?

Bio-Rad Laboratories employs 8,000 workers across the globe.

Does Bio-Rad Laboratories have any subsidiaries?

The following companies are subsidiares of Bio-Rad Laboratories: BIO-RAD spol. s r.o., Bio-Metrics (U.K.) Limited, Bio-Metrics Limited, Bio-Metrics Properties Limited, Bio-Rad (France), Bio-Rad (Shanghai) Life Science Research & Development Co. Ltd., Bio-Rad 1, Bio-Rad AbD Serotec GmbH, Bio-Rad AbD Serotec Ltd, Bio-Rad China Ltd., Bio-Rad Denmark ApS, Bio-Rad Europe GmbH, Bio-Rad Export LLC, Bio-Rad France, Bio-Rad France Holding, Bio-Rad Germany Holding GmbH, Bio-Rad Haifa Ltd., Bio-Rad Holdings LLC, Bio-Rad Hungary Trading LLC, Bio-Rad IHC Europe GmbH, Bio-Rad Innovations, Bio-Rad Korea Ltd., Bio-Rad Laboratories (Canada) Limited, Bio-Rad Laboratories (India) Private Limited, Bio-Rad Laboratories (Israel) Inc., Bio-Rad Laboratories (Pty) Ltd, Bio-Rad Laboratories (Shanghai) Co. Ltd., Bio-Rad Laboratories (Singapore) Pte Ltd, Bio-Rad Laboratories AB, Bio-Rad Laboratories AG, Bio-Rad Laboratories B.V., Bio-Rad Laboratories Ges.m.b.H., Bio-Rad Laboratories GmbH, Bio-Rad Laboratories K.K., Bio-Rad Laboratories Limited, Bio-Rad Laboratories Logistik GmbH, Bio-Rad Laboratories Ltd., Bio-Rad Laboratories M.EPE, Bio-Rad Laboratories NV, Bio-Rad Laboratories Pty Ltd, Bio-Rad Laboratories S.A., Bio-Rad Laboratories S.r.l., Bio-Rad Laboratories SAS, Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios Lda, Bio-Rad Laboratorii OOO, Bio-Rad Laboratórios Brasil Ltda., Bio-Rad Luxembourg S.à r.l., Bio-Rad Medical Diagnostics GmbH, Bio-Rad Middle East FZ-LLC, Bio-Rad Norway AS, Bio-Rad Pacific Limited, Bio-Rad Polska Sp. z o.o., Bio-Rad QL Inc., Bio-Rad S.A., Bio-Rad Services France, Bio-Rad Services UK Limited, Blackhawk Biosystems, Bridger Technologies Inc., Celsee, DiaMed (G.B.) Ltd, DiaMed (Schweiz) GmbH, DiaMed Benelux NV, DiaMed Diagnostika Deutschland GmbH, DiaMed Fennica Oy, DiaMed France SA, DiaMed GmbH, DiaMed Holding AG, DiaMed Holding GmbH, DiaMed Latino-América S.A., DiaMed S.E.A. Limited, DiaMed Österreich GmbH, Distribudora de Analítica para la Medicina Ibérica S.A.U., GnuBIO Inc., IMV Medical Information Division Inc., International Marketing Ventures Ltd., MJ GeneWorks, QuantaLife, Raindance Technologies Limited, Raindance Techologies Inc., Research Specialties for Laboratories NV, Respiratory Diagnostics Inc., and Wuxi BioCanal Nano Technology Co. Ltd..

When was Bio-Rad Laboratories founded?

Bio-Rad Laboratories was founded in 1952.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is www.bio-rad.com.

Where are Bio-Rad Laboratories' headquarters?

Bio-Rad Laboratories is headquartered at 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]


This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.